Application of ailanthus altissima type triterpenoid or glucoside thereof in preparation of liver protection medicine
The glycosyltransferase enzymatic reaction of syringon-type triterpenes was solved by solving the scarce resources and insufficient biosynthesis research of syringon-type 6-6-5 ring triterpenes, and a new chemical entity with liver-protective activity was obtained Molecules, used to treat drug-induced liver injury.
Patent Information
- Application Number
- CN202310611389.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-05-26
AI Technical Summary
The natural resources of stinky 6-6-5 cyclic triterpenes are scarce, chemical synthesis is difficult, and biosynthetic cyclase and its genes are limited, especially the enzyme method to synthesize active stinky 6-6-5 cyclic triterpenes or their The application of analogs is rarely studied.
Glycosyltransferase is used to glycosylate and modify the stinky triterpenes to obtain stinky triterpenes with liver-protecting activity. UDP-glucose is used as a glycosyl donor to generate monoglycosides or disaccharides through enzymatic reactions. Specifically, The glycosyltransferase with amino acid sequences of SEQ ID NO.1 and SEQ ID NO.2 is subjected to enzymatic reaction.
New chemical entity molecules are provided for the development of liver disease drugs, especially in the treatment of drug-induced liver injury, such as protective effects on hepatocyte damage caused by paracetamol.
Smart Images

Figure BDA0004252549500000021 
Figure BDA0004252549500000022 
Figure BDA0004252549500000041
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to the application of Ailanthus altissima type triterpenoid compounds or glycosides thereof in the preparation of liver protection drugs. Background Art
[0002] Triterpenes are a class of compounds with a wide range of biological and pharmacological activities. The most widely distributed triterpenes in plants are tetracyclic triterpenes and pentacyclic triterpenes, while Ailanthus-type 6-6-5-cyclic triterpenes are relatively rare. So far, more than 50 Ailanthus and its Ailanthus glycoside compounds have been reported in plants (Domingo, V.; Arteaga, JF; Quílez Del Moral, JF; Barrero, AF Unusually Cyclized Triterpenes: Occurrence, Biosynthesis and Chemical Synthesis. Nat. Prod. Rep. 2009, 26, 115–134. Stonik, VA; Kolesnikova, SAMalabaricane and Isomalabaricane Triterpenoids, Including Their Glycoconjugated Forms. Mar. Drugs 2021, 19, 327. (c) Xu, R.; Fazio, GC; Matsuda, SP On the Origins of Triterpenoid Skeletal Diversity. Phytochemistry 2004, 65, 261–291.).
[0003] In summary, the current research on Ailanthus-type 6-6-5-cyclic triterpenes and their analogs has the following limitations and shortcomings: on the one hand, there are few natural resources of Ailanthus-type 6-6-5-cyclic triterpenes and chemical synthesis is difficult; on the other hand, the relevant research on the cyclase and its genes responsible for the biosynthesis of Ailanthus-type 6-6-5-cyclic triterpenes skeleton is very limited, especially the application research on enzymatic synthesis of active Ailanthus-type 6-6-5-cyclic triterpenes or their analogs is very rare. Summary of the invention
[0004] The present invention provides an application of an Ailanthus altissima triterpene compound or a glycoside thereof in preparing a drug for preventing or treating liver disease. The Ailanthus altissima triterpene has a structure as shown in Formula 1 or 2;
[0005]
[0006] In some embodiments of the present invention, the glycoside is a monosaccharide or a disaccharide of the Ailanthus altissima type triterpene compound.
[0007] In some embodiments of the present invention, the glycoside is a glucoside of the Ailanthus altissima-type triterpene compound.
[0008] In some embodiments of the present invention, the glycoside of the Ailanthus triterpenoid compound is obtained by enzymatic reaction using the Ailanthus triterpenoid compound as a glycosyl acceptor and a glycosyltransferase, and the enzymatic reaction preferably uses UDP-glucose as a glycosyl donor.
[0009] In some embodiments of the present invention, the glycosyltransferase used in the enzymatic reaction has an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.2.
[0010] In some embodiments of the present invention, the glycoside of the Ailanthus type triterpene compound has a structure as shown in Formula 1a or 1b:
[0011]
[0012] In some embodiments of the present invention, the liver disease is drug-induced liver injury, such as liver injury caused by drugs such as paracetamol.
[0013] Additional Notes
[0014] Unless otherwise specified, the scientific and technological terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The present invention may also be implemented using any methods and materials similar to or equivalent to those described herein, and specific implementation methods and preferred methods and materials are described herein without limiting the present invention in any way.
[0015] Beneficial technical effects
[0016] The present invention finds that specific Ailanthus triterpenoid compounds have potential application value in the research and development of drugs for treating liver diseases. The present invention further uses glycosyltransferase to perform glycosylation modification on Ailanthus triterpenoid compounds to obtain Ailanthus triterpenoid glycosides with liver-protective activity, providing new chemical entity molecules for the research and development of new drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 , HR-SEI-MS spectrum of compound 1a;
[0018] Figure 2 , IR spectrum of compound 1a;
[0019] Figure 3 , HR-SEI-MS spectrum of compound 1b;
[0020] Figure 4 , IR spectrum of compound 1b. DETAILED DESCRIPTION
[0021] The following specific examples are provided to further illustrate various aspects of the present invention. These examples are non-limiting and should not be construed as limiting any aspect of the present invention. The scope of protection of the present invention is limited only by the claims. Without departing from the scope of the claims, those skilled in the art may make various modifications and improvements to various aspects of the present invention, and these modifications and improvements also belong to the scope of protection of the present invention. For example, replacing the promoter and expression vector used in the examples with other promoters and expression vectors commonly used in the art is something that can be understood and implemented by those of ordinary skill in the art.
[0022] In addition, it should be noted that, unless otherwise specified, the various materials and reagents used in the following examples are commonly used materials and reagents in the art and can be obtained through conventional commercial channels; the methods used are conventional methods known to those skilled in the art.
[0023] Example 1: Preparation and structural analysis of glycosylation products
[0024] 0.4mM compound 1 (Arabidiol) was used as the glycosyl acceptor, 0.8mM UDP-glucose (UDP-Glc) was used as the glycosyl donor, 2mg / mL pure enzyme of glycosyltransferase was added, and the in vitro enzymatic reaction of 20mL system was carried out in 50mM Tris-HCl buffer. The reaction was carried out in a water bath at 35℃ for 16h, and the reaction was terminated when the substrate was no longer converted by HPLC. The reaction solution was extracted 3 times with water-saturated n-butanol, the organic layer was evaporated to dryness under reduced pressure, and the methanol was re-dissolved and filtered and purified by reverse semi-preparative HPLC. Elution conditions: 100% acetonitrile isocratic elution; flow rate: 3mL / min; column temperature: 30℃. The prepared glycosylation product was dissolved in deuterated pyridine, and 1D NMR and 2D NMR tests were performed, and IR and ORD were tested at the same time.
[0025] Glycosyltransferase AmUGTa (having the amino acid sequence shown in SEQ ID NO.1) was used for enzymatic reaction to obtain new compound 1a. According to HR-ESI-MS ( Figure 1 ) Determine the molecular formula of 1a to be C 36 H 62 O7. Combining 1D NMR and 2D NMR spectra to assign NMR data (Table 1), the structure of 1a was identified as arabidiol3-O-β-D-glucoside (IR spectrum as shown in Figure 2 shown).
[0026] Glycosyltransferase AmUGTb (having the amino acid sequence shown in SEQ ID NO.2) was used for enzymatic reaction to obtain new compound 1b. According to HR-ESI-MS ( Figure 3) Determine the molecular formula of 1b to be C 42 H 72 O 12 Combining 1D NMR and 2D NMR spectra to assign NMR data (Table 1), the structure of 1b was identified as 3-(2′-O-β-D-glucopyranosy)-O-β-D-glucopyranosyl arabidiol (IR spectrum as shown in Figure 4 shown).
[0027] Table 1: Compounds 1a and 1b 1 H and 13 C NMR (δinppm, Jin Hz)
[0028]
[0029]
[0030] Example 2: Protective effect on paracetamol-induced hepatocyte damage in vitro
[0031] The MTT method was used to detect the protective effects of Ailanthus triterpenoids 1-7 and Ailanthus triterpenoid glycosides 1a and 1b against paracetamol-induced hepatocyte injury in vitro.
[0032] The structures of compounds 3 to 7 are shown below:
[0033]
[0034] HepG2 cells were inoculated in a 96-well cell culture plate. After culturing for 24 hours, non-toxic concentrations of the test compound and paracetamol (APAP, final concentration 8mM) were added. At the same time, a positive drug control group (glutathione GSH), a solvent blank control group and a model group were set up. The cells were continued to act for 24 hours. The culture medium was discarded, and 100μl of MTT (0.5mg / ml) solution was added to each well. The culture was continued for 4 hours. The MTT solution was discarded, and 150μl of DMSO was added to each well. The mixture was shaken on an oscillator, and the absorbance value was measured at a wavelength of 570nm on an ELISA reader. Cell survival rate (%) = (mean OD of the drug group / mean OD of the solvent control group) × 100%.
[0035] From the results shown in Table 2, it can be seen that compounds 2 and 1a have significant hepatoprotective activity and can be used as lead compounds for the development of hepatoprotective drugs.
[0036] Table 2: Results of hepatoprotective activity of compounds
[0037]
[0038] Note: *** P<0.001, ##P<0.01,and # P<0.05
Claims
1. Use of Ailanthus altissima triterpenoid compounds or glycosides thereof in the preparation of drugs for preventing or treating liver diseases, characterized in that: The Ailanthus altissima triterpenoid has a structure as shown in Formula 1 or 2; 2. The use according to claim 1, characterized in that: The glycoside is a monoglycoside or a disaccharide glycoside of the Ailanthus altissima type triterpene compound.
3. The use according to claim 1 or 2, characterized in that: The glycoside is the glucoside of the Ailanthus altissima type triterpene compound.
4. The use according to claim 1, characterized in that: The glycoside of the Ailanthus altissima triterpenoid compound is obtained by using the Ailanthus altissima triterpenoid compound as a glycosyl acceptor and performing an enzymatic reaction using a glycosyltransferase; preferably, UDP-glucose is used as a glycosyl donor.
5. The use according to claim 4, characterized in that: The glycosyltransferase has an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.
2.
6. The use according to claim 1, characterized in that: The glycoside of the Ailanthus altissima triterpenoid compound has a structure as shown in Formula 1a or 1b:
7. The use according to claim 1, characterized in that: The liver disease is drug-induced liver injury.
Citation Information
Patent Citations
Preparation method and application of triterpenoid with immunosuppressive activity
CN103304529A
Ailanthus altissima triterpene as well as application and preparation method thereof
CN115181144A
Anti-tumor activity of aechl-1, novel triterpenoid isolated from ailanthus excelsa in vitro and in vivo
US20100311987A1
